Medtronic to buy Contego Medical for $380M
Medtronic plans to acquire Contego Medical, a privately held medical device company, for $380 million. The deal will expand Medtronic's carotid disease treatments and is expected to close in Q3 of its fiscal year. Medtronic expects minimal dilution to earnings in fiscal 2027 and 2028, then neutrality or accretion after that.
How this was made
The 30-second read
Why it matters
Medtronic’s acquisition adds carotid revascularization capabilities and complements its Liberant thrombectomy system, with a defined $380M valuation and an EPS impact trajectory through fiscal 2028.
Market read
Traders can update MDT’s deal-implied valuation and forward EPS expectations based on the disclosed price, timing, and dilution-to-accretion profile.
What to watch
Regulatory and integration timelines for device portfolios, plus reliance on the existing Contego exclusive US distribution agreement, could drive outcomes more than the headline valuation.
Background
Contego is a privately held device company focused on carotid artery disease and peripheral thrombectomy, including the Neuroguard IEP carotid stent system and Excipio thrombectomy device.
Ticker impact
Medtronic plans to acquire Contego Medical for $380M, expanding carotid disease treatments and targeting completion in fiscal Q3 2027.
Likely modest upside as investors price in portfolio expansion, offset by deal execution and integration uncertainty.
The article discloses a specific $380M acquisition, timing (fiscal Q3), and EPS impact profile, which are direct inputs to near-term valuation and risk assessment.
Market effects
Reinforces consolidation in neurovascular and peripheral vascular device markets, potentially increasing competitive focus on carotid revascularization platforms.
Limited direct regional read-through; primarily US-focused distribution and device commercialization.
Could modestly affect global medtech M&A expectations in vascular intervention, but impact is company-specific.
Counterpoint
The stated “minimally dilutive” and later accretion may still be optimistic if Contego’s clinical adoption or reimbursement dynamics lag expectations.
Key entities
- acquirerMedtronic
Plans to buy Contego Medical for $380M and expand its carotid disease and thrombectomy portfolio.
- targetContego Medical
Privately held neurovascular and peripheral thrombectomy device company with Neuroguard IEP and Excipio products.
- executiveDavid Moeller
Medtronic SVP and president of Peripheral Vascular Health, quoted on the strategic rationale.


